Outset Medical (OM) insider sell-to-cover 224 shares for taxes reported

Rhea-AI Filing Summary

Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 224 shares of common stock on 01/07/2026 at a price of $4.27 per share. After this transaction, he beneficially owned 46,271 shares directly.

The filing explains that the sale was a required "sell to cover" transaction to satisfy tax withholding obligations tied to 447 shares of common stock underlying performance stock units that had been earned and vested, and it did not represent a discretionary trade by Brottem.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brottem John L.

(Last) (First) (Middle)

3052 ORCHARD DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Outset Medical, Inc. [ OM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		S(1)		224	D	$4.27	46,271	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with 447 shares of Common Stock underlying PSUs (i) which were, as previously reported, originally earned based on the achievement of applicable performance criteria as of December 31, 2024 or January 6, 2025, as applicable, as certified by the Compensation Committee of the Issuer's Board of Directors on January 17, 2025 and (ii) vested and were released on January 6, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

	John L Brottem	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Outset Medical (OM) report in this Form 4?

Outset Medical (OM) reported that General Counsel John L. Brottem sold 224 shares of common stock on 01/07/2026 at $4.27 per share and held 46,271 shares afterward.

Who is the reporting person in Outset Medical (OM)'s latest Form 4?

The reporting person is John L. Brottem, who serves as General Counsel of Outset Medical, Inc.

Was the Outset Medical (OM) insider stock sale a discretionary trade?

No. The filing states the sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by John L. Brottem.

How many shares did the Outset Medical (OM) insider sell and at what price?

John L. Brottem sold 224 shares of Outset Medical common stock at a price of $4.27 per share.

How many Outset Medical (OM) shares does the insider own after the reported sale?

Following the transaction, John L. Brottem beneficially owned 46,271 shares of Outset Medical common stock in direct ownership.

What awards were related to the tax withholding sale reported by Outset Medical (OM)?

The tax withholding sale related to 447 shares of common stock underlying performance stock units (PSUs) that were earned based on performance criteria, then vested and were released on January 6, 2025.